Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX OTCMKTS:ETST NASDAQ:HUMA NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.31+8.7%$2.40$1.28▼$7.85$253.29M1.161.55 million shs3.20 million shsETSTEarth Science Tech$0.20+7.4%$0.19$0.00▼$0.25$58.86M1.91101,541 shs26,024 shsHUMAHumacyte$1.48-1.7%$2.04$1.15▼$6.77$233.60M1.873.95 million shs1.53 million shsSGMTSagimet Biosciences$7.11+3.2%$8.49$1.73▼$11.41$231.26M3.351.05 million shs421,909 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-4.07%+2.42%-10.17%-15.87%-65.92%ETSTEarth Science Tech-3.37%+5.80%-4.51%+29.31%+16.38%HUMAHumacyte+6.38%-0.66%-39.52%-40.94%-72.17%SGMTSagimet Biosciences-1.99%-6.39%-21.08%+11.31%+118.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.31+8.7%$2.40$1.28▼$7.85$253.29M1.161.55 million shs3.20 million shsETSTEarth Science Tech$0.20+7.4%$0.19$0.00▼$0.25$58.86M1.91101,541 shs26,024 shsHUMAHumacyte$1.48-1.7%$2.04$1.15▼$6.77$233.60M1.873.95 million shs1.53 million shsSGMTSagimet Biosciences$7.11+3.2%$8.49$1.73▼$11.41$231.26M3.351.05 million shs421,909 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-4.07%+2.42%-10.17%-15.87%-65.92%ETSTEarth Science Tech-3.37%+5.80%-4.51%+29.31%+16.38%HUMAHumacyte+6.38%-0.66%-39.52%-40.94%-72.17%SGMTSagimet Biosciences-1.99%-6.39%-21.08%+11.31%+118.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.75Moderate Buy$12.50442.30% UpsideETSTEarth Science Tech 0.00N/AN/AN/AHUMAHumacyte 2.88Moderate Buy$9.75561.02% UpsideSGMTSagimet Biosciences 3.00Buy$25.67260.94% UpsideCurrent Analyst Ratings BreakdownLatest ETST, ANNX, SGMT, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/18/2025ANNXAnnexonZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/12/2025HUMAHumacyteTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $3.508/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/11/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/11/2025SGMTSagimet BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$28.008/7/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$29.007/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.007/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/AETSTEarth Science Tech$33.12M1.78$0.01 per share16.65$0.01 per share20.00HUMAHumacyte$1.57M148.79N/AN/A($0.41) per share-3.60SGMTSagimet BiosciencesN/AN/AN/AN/A$5.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%11/13/2025 (Estimated)ETSTEarth Science Tech$3.25MN/A0.00∞N/A7.93%72.31%41.28%11/13/2025 (Estimated)HUMAHumacyte-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)SGMTSagimet Biosciences-$45.57M-$1.83N/AN/AN/AN/A-39.88%-38.40%11/13/2025 (Estimated)Latest ETST, ANNX, SGMT, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ANNXAnnexon-$0.36-$0.34+$0.02-$0.34N/AN/A8/13/2025Q2 2025SGMTSagimet Biosciences-$0.52-$0.32+$0.20-$0.32N/AN/A8/11/2025Q2 2025HUMAHumacyte-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.675.67ETSTEarth Science Tech0.010.910.67HUMAHumacyte2.972.451.93SGMTSagimet BiosciencesN/A17.5517.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AETSTEarth Science TechN/AHUMAHumacyte44.71%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%ETSTEarth Science Tech24.90%HUMAHumacyte5.10%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.89 million95.96 millionOptionableETSTEarth Science Tech3294.30 million221.02 millionNot OptionableHUMAHumacyte150158.37 million150.30 millionOptionableSGMTSagimet Biosciences832.52 million27.74 millionOptionableETST, ANNX, SGMT, and HUMA HeadlinesRecent News About These CompaniesSagimet Biosciences announces presentations at MASH Drug Development Summit1 hour ago | msn.comSagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development SummitSeptember 10 at 7:00 AM | globenewswire.comAlyeska Investment Group L.P. Sells 98,069 Shares of Sagimet Biosciences Inc. $SGMTSeptember 8 at 5:14 AM | marketbeat.comWall Street Zen Upgrades Sagimet Biosciences (NASDAQ:SGMT) to "Hold"September 8 at 2:41 AM | marketbeat.comSagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7 at 11:01 PM | seekingalpha.comSagimet Biosciences (NASDAQ:SGMT) Stock Rating Upgraded by Wall Street ZenSeptember 7 at 2:31 AM | americanbankingnews.comSagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At HoldAugust 31, 2025 | seekingalpha.comSagimet Gains Momentum As FDA Eases Path For MASH Drug DevelopmentAugust 29, 2025 | seekingalpha.comSagimet Biosciences to Participate in Two Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by BrokeragesAugust 21, 2025 | marketbeat.comSagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?August 20, 2025 | zacks.comAfter Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)August 20, 2025 | zacks.comWhat is Wedbush's Estimate for SGMT Q2 Earnings?August 16, 2025 | marketbeat.comSagimet Biosciences Enters New Sales Agreement with LeerinkAugust 15, 2025 | msn.comSagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 13, 2025 | finanznachrichten.deSagimet Biosciences Tops Q2 EPS ForecastAugust 13, 2025 | aol.comASagimet Biosciences Reports Positive Phase 3 Results for Denifanstat in Acne and Initiates Phase 1 Trials for FASN InhibitorsAugust 13, 2025 | quiverquant.comQSagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 13, 2025 | globenewswire.comWedbush Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform RecommendationAugust 12, 2025 | msn.comWedbush Begins Coverage on Sagimet Biosciences (NASDAQ:SGMT)August 12, 2025 | marketbeat.comSagimet Biosciences initiated with an Outperform at WedbushAugust 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETST, ANNX, SGMT, and HUMA Company DescriptionsAnnexon NASDAQ:ANNX$2.31 +0.19 (+8.73%) Closing price 03:59 PM EasternExtended Trading$2.28 -0.02 (-0.87%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Earth Science Tech OTCMKTS:ETST$0.20 +0.01 (+7.41%) As of 11:22 AM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.Humacyte NASDAQ:HUMA$1.48 -0.03 (-1.67%) Closing price 03:59 PM EasternExtended Trading$1.49 +0.01 (+1.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Sagimet Biosciences NASDAQ:SGMT$7.11 +0.22 (+3.21%) Closing price 03:59 PM EasternExtended Trading$7.12 +0.01 (+0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
